Menu
Lilly unites caring with discovery to create medicines that make life better for people around the world. Over 47 million people count on Lilly medicines each year. In the nearly 150 years we’ve been in business, we’ve developed and delivered trusted medicines that help people get better, feel better and live better.

Inclusive representation in clinical trials is critical – it helps our researchers ensure that we’re making medicines that will be as effective as possible for patients who use them. 
Learn More About Lilly Trials

LEARN MORE ABOUT LILLY TRIALS

Lilly’s partnership with BlackDoctor aims to educate and encourage clinical trial participation and awareness.
Weight Management
Cardiovascular
Diabetes
Neurological Disorders
Pain
Cancer
Immunology
Pediatrics

A Study Investigating Tersolisib (LY4064809) or Placebo Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with Breast Cancer with a PIK3CA Mutation
Condition:  Advanced Breast Cancer

A Phase 3, Randomized, Double‑blind, Placebo‑controlled Study of LY4064809 (tersolisib) in Combination with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2‑ Advanced Breast Cancer with a PIK3CA Mutation (PIKALO‑2)

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Testing For: LY4064809 (Tersolisib)
Trial ID: J6M-MC-JSGD (PIKALO-2)
Age: 18+ years old
Phase: 2/3
Learn More

A Phase 3 Study of Olomorasib in Combination with Standard of Care in Participants with Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)
Condition:  Non-Small Cell Lung Cancer
Testing For: olomorasib (LY3537982)
Trial ID: J3M-MC-JZQH
Age: 8+
Phase: 3
Learn More

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/mirikizumab co-administration compared with mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease
Condition:  Crohn’s Disease
Testing for: Mirikizumab (LY3074828) and LY4395089
Trial ID: J6Z-MC-CD01
Age: 18 to 80
Phase: 2
Learn More

A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer (SUNRAY-02)
Condition:  Non-Small Cell Lung Cancer
Testing For: Olomorasib (LY3537982)
Trial ID: J3M-MC-JZQB
Age: Age: 18+
Learn More

A clinical trial for people who have irritable bowel syndrome with diarrhea (GZMS) (RENEW-IBS-D)
Condition:  Irritable Bowel Syndrome-Diarrhea (IBS-D)
What the trial is testing: Brenipatide
Trial ID: J3S-MC-GZMS
Age: 18 to 75 years of age
Phase: 2
Learn More

A Clinical trial for people with irritable bowel syndrome with constipation (GZMT) (RENEW-IBS-C)
Condition:  Irritable Bowel Syndrome-Constipation (IBS-C)
What the trial is testing: Brenipatide
Trial ID: J3S-MC-GZMT
Age: 18 to 75 years of age
Phase: 2
Learn More

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET).
Condition:  Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease
Drugs: LY4268989 (MORF-057)
Trial ID: J6E-MC-KWAB
Age: 18 to 85
Phase: 2
Learn More

Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo
Condition:  Non-Segmental Vitiligo
Testing For: XCL1/2 (LY4005130)
Trial ID: J5D-MC-FPAD
Age: 18 to ≤75 years of age
Phase: 2
Learn More

Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Severe Alopecia Areata
Condition:  Severe Alopecia Areata
Testing For: XCL1/2 (LY4005130)
Trial ID: J5D-MC-FPAC
Age: 18 to ≤50 years of age
Phase: 2
Learn More

EMERALD-3: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis
Condition:  Ulcerative Colitis
Testing for: LY4268989 (MORF-057)
Trial ID: J6E-MC-KWAM
Age: 18 - 80
Phase: 2 and 3
Learn More

A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)
Condition:  Ovarian Cancer
Testing for: LY4170156, mirvetuximab soravtansine, topotecan, bevacizumab, paclitaxel, carboplatin, gemcitabine
Trial ID: J5E-MC-JZXB
Age: ≥18 years
Phase: 3
Learn More

FORAGER-2 Study: A clinical research study for people living with bladder cancer and a change in the FGFR3 gene
Condition:  Bladder Cancer
A Study Investigating Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Trial ID: J4G-MC-JZVD
Age: ≥18 years
Phase: 3
Learn More

TOPAZ-UC: A Phase 2, Multicenter, Randomized, Double-Blind, Active- Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Condition:  Ulcerative Colitis
Drugs: LY4268989 (MORF-057) and Mirikizumab (LY3074828)
Trial ID: J6E-MC-KWAN
Age: 18-80
Phase: 2
Learn More
Weight Management

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight (COMMIT-CD)
Condition:  Crohn’s Disease, Obesity
Drugs: Mirikizumab, Tirzepatide
Trial ID: I6T-MC-AMCE
Age: 18-70 years
Phase: 3
Learn More
Weight Management

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) Conditions the trial is for: Ulcerative Colitis, Obesity
Condition:  Ulcerative Colitis, Obesity
Trial ID: I6T-MC-AMCD
Age: 18-70 Years old
Phase: 3
Learn More

Where Culture Meets Care

BlackDoctor is the world’s largest and most comprehensive online health resource specifically for the Black community. BlackDoctor understands that the uniqueness of Black culture - our heritage and our traditions - plays a role in our health. BlackDoctor gives you access to innovative new approaches to the health information you need in everyday language so you can break through the disparities, gain control and live your life to its fullest.
CATEGORIES
COMPANY INFO
LEGAL
OUR BRANDS
Copyright © 2026, BlackDoctor, Inc. All rights reserved.
✦ AI Search Disclaimer
This AI-powered search tool helps you find relevant health articles from the BlackDoctor.org archive. Please keep the following in mind:
✦ For Informational Purposes Only
The information provided through this AI search is for general educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment.
✦ Always Consult a Healthcare Provider
Never disregard professional medical advice or delay seeking it because of something you have read through this search tool. If you have a medical emergency, call your doctor or 911 immediately.
✦ AI Limitations
This search tool uses artificial intelligence to help match your queries with articles in our archive. While we strive for accuracy, AI-generated results may occasionally be incomplete, outdated, or not fully relevant to your specific situation.
✦ No Doctor-Patient Relationship
Using this search tool does not create a doctor-patient relationship between you and BlackDoctor.org or any healthcare provider.
Explore over 35,000 articles and videos across black health, wellness, lifestyle and culture
Full AI Search Experience >
×

Download PDF

Enter your name and email to receive the download link.